HIV/AIDS News

LOS ANGELES —In this video from IDWeek, Vani Vannappagari, MBBS, PhD, MPH, global head of epidemiology and real-world evidence at ViiV Healthcare, discusses study findings demonstrating the effectiveness of cabotegravir for HIV prevention.

Less than 3% of patients tested for a bacterial STI in nearly a dozen EDs were also tested for HIV, demonstrating widespread nonadherence to a CDC recommendation, according to a study presented at IDWeek.

A significant number of Medicaid-insured infants infected with HIV in the first year of their life did not receive postnatal antiretroviral prophylaxis, a study presented at IDWeek showed.

LIMA, Peru — Healio is on site for the International AIDS Society’s HIV Research for Prevention Conference, which will take place from Oct. 6 to 10.

Twice-yearly injectable lenacapavir for HIV prevention reduced HIV infections by 96% compared with background HIV incidence and demonstrated superiority over a once-daily pill for PrEP in a phase 3 trial, Gilead Sciences announced Thursday.

HHS this week announced that it will allocate more than $1.4 billion in funding through the Ryan White HIV/AIDS Program to help people with HIV who have low incomes receive medication and care.

Two experimental HIV vaccine regimens failed to reduce infections in a 3-year trial in eastern and southern Africa compared with participants who were taking a placebo, some of whom were on oral PrEP, according to a study.

Testing HIV PrEP users for STIs every 6 months did not increase the risk for STIs compared with testing them every 3 months and could reduce the cost of PrEP programs, according to a study.

Three-quarters of people globally living with HIV are on ART, a roughly 30% increase during the last nine years, and fewer people acquired HIV in 2023 than at any point since the late 1980s, UNAIDS reported.